

Declaration of Conformity of the Management Board and the Supervisory Board of BioNTech SE with the German Corporate Governance Code (“Code”) pursuant to Section 161 of the German Stock Corporation Act (*AktG*).

The Management Board and Supervisory Board have dealt in detail with the recommendations of the Corporate Governance Code (“Code”) and on 20 March 2023 adopted the following Declaration of Conformity pursuant to Section 161 (1) of the German Stock Corporation Act (*AktG*):

With the exception of the points listed below, BioNTech SE (“Company”) has complied with all recommendations of the Code in the version from 28 April 2022 and will continue to comply with them in the future.

- According to Item B.1 of the Code, the Supervisory Board shall pay attention to diversity in the composition of the Management Board. On 4 May 2020, the Supervisory Board of the Company set the target for the proportion of women on the Management Board at 25 %. Mr. Jens Holstein was appointed to the Management Board as Chief Financial Officer on 1 July 2021. In the run-up to Mr. Holstein's appointment, extensive selection processes took place with several female and male candidates. As a result, Mr. Holstein was appointed on the basis of his expertise, his many years of experience and his profile as Chief Financial Officer, as he was the most suitable candidate for the position of Chief Financial Officer and the best fit for the Company compared to all other candidates. Last year, individual board members' contracts were renewed without appointing a new board member. This was done after careful consideration and discussion and, in the view of the Supervisory Board, was in the best interest of the Company. On 8 March 2023, the Supervisory Board again dealt with the proportion of women on the Management Board and set the target figure at 25%. The deadline by which this target is to be achieved was set at 31 December 2025. The Supervisory Board is working on the new target values set with regard to diversity on the Management Board and will continue to take these into account in the future.
- According to Item C.1 of the Code, the Supervisory Board shall pay attention to diversity, among other things, for its composition. The Supervisory Board was expanded in the 2022 financial year. Prof. Dr. Anja Morawietz and Prof. Dr. Rudolf Staudigl were elected to the Supervisory Board by the Annual General Meeting. Thus, the targeted quota of women on the Supervisory Board, which was to be 25% by 31 December 2022, was not achieved. In preparation for the election proposals for the 2022 Annual General Meeting, a large number of female and male candidates were interviewed. By the time the invitation to the Annual General Meeting was published, two female candidates had been shortlisted. In order to cover the required competence profile in the best possible way, the Supervisory Board decided, after intensive deliberations and taking into account the interests of the Company, to propose Prof. Dr Anja Morawietz and Prof. Dr Rudolf Staudigl for election as a further member of the Supervisory Board. On 8 March 2023, the Supervisory Board again addressed the issue of the proportion of women on the Supervisory Board and set the target at 25%. The deadline by which this target figure is to be reached was set at 31 December 2025. The issue of diversity is of central importance to the Supervisory Board and the Company and shall be given special consideration in the upcoming Supervisory Board elections.
- According to Item C.7 of the Code, it is recommended that more than half of the members of the Supervisory Board be independent of the company and the Management Board. Accordingly, a Supervisory Board member is independent of the company and its Management Board if he or she has no personal or business relationship with the company or its Management Board that could constitute a material and not merely temporary conflict of interest. In assessing independence, the length of service on the Supervisory Board shall be taken into account, among other factors. Despite the fact that three out of six members of the Supervisory Board have been on the Supervisory Board for longer than recommended by the Code, all members of the Supervisory Board are considered to be independent. The Supervisory Board considers it advantageous and essential for the Company to maintain the knowledge and experience currently available on the Board. This includes many years of knowledge of the Company and its industry as well as comprehensive professional knowledge in the areas of finance, economics, science and the capital market, which is particularly important in view of the current, steady global growth and change of the Company. Due to the long-standing relationship with the Company and the existing economic independence from the Company, as well

as the absence of other concerns that could cause possible conflicts of interest, the length of membership of the three Supervisory Board members Mr. Helmut Jeggle, Mr. Michael Motschmann and Prof. Christoph Huber M.D. does not conflict with their respective independence. (see Item C.8 of the Code)

Mainz, 20 March 2023

BioNTech SE

Management Board

Prof. Dr. Ugur Sahin
Chief Executive Officer, CEO

Jens Holstein
Chief Financial Officer, CFO

Supervisory Board

Helmut Jeggle
Chairman of the Supervisory Board